Back to News & Events

Life Sciences Summit 2018: 10/24-10/25

The Center for Biotechnology’s annual Life Sciences Summit is an early-stage investor and business development conference for emerging companies and academic innovators. This year’s event will take place on October 24-25 at 10 on the Park at the Time Warner Center in New York City.

The objective of the meeting is to connect emerging companies with early-stage investors, business development professionals, and medical research foundations with the goal of advancing new innovations through clinical development. The robust, two-day program features:

– Emerging Company Showcase
– Pitch Doctor Sessions
– Pipeline Café
– Business Workshops & Plenary Sessions
– Therapeutic Focused Panels
– Online & Onsite Partnering
– Strategic partners presentations

View the full 2018 program and register at lifesciencessummit.org.

Related Stories

WP_Query Object
(
    [query] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
        )

    [query_vars] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
            [error] => 
            [m] => 
            [p] => 0
            [post_parent] => 
            [subpost] => 
            [subpost_id] => 
            [attachment] => 
            [attachment_id] => 0
            [name] => 
            [pagename] => 
            [page_id] => 0
            [second] => 
            [minute] => 
            [hour] => 
            [day] => 0
            [monthnum] => 0
            [year] => 0
            [w] => 0
            [category_name] => 
            [tag] => 
            [cat] => 
            [tag_id] => 
            [author] => 
            [author_name] => 
            [feed] => 
            [tb] => 
            [paged] => 0
            [meta_key] => 
            [meta_value] => 
            [preview] => 
            [s] => 
            [sentence] => 
            [title] => 
            [fields] => 
            [menu_order] => 
            [embed] => 
            [category__in] => Array
                (
                )

            [category__not_in] => Array
                (
                )

            [category__and] => Array
                (
                )

            [post__in] => Array
                (
                )

            [post__not_in] => Array
                (
                )

            [post_name__in] => Array
                (
                )

            [tag__in] => Array
                (
                )

            [tag__not_in] => Array
                (
                )

            [tag__and] => Array
                (
                )

            [tag_slug__in] => Array
                (
                )

            [tag_slug__and] => Array
                (
                )

            [post_parent__in] => Array
                (
                )

            [post_parent__not_in] => Array
                (
                )

            [author__in] => Array
                (
                )

            [author__not_in] => Array
                (
                )

            [search_columns] => Array
                (
                )

            [ignore_sticky_posts] => 
            [suppress_filters] => 
            [cache_results] => 1
            [update_post_term_cache] => 1
            [update_menu_item_cache] => 
            [lazy_load_term_meta] => 1
            [update_post_meta_cache] => 1
            [nopaging] => 
            [comments_per_page] => 50
            [no_found_rows] => 
            [order] => 
        )

    [tax_query] => WP_Tax_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => AND
            [table_aliases:protected] => Array
                (
                )

            [queried_terms] => Array
                (
                )

            [primary_table] => wp_posts
            [primary_id_column] => ID
        )

    [meta_query] => WP_Meta_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => 
            [meta_table] => 
            [meta_id_column] => 
            [primary_table] => 
            [primary_id_column] => 
            [table_aliases:protected] => Array
                (
                )

            [clauses:protected] => Array
                (
                )

            [has_or_relation:protected] => 
        )

    [date_query] => 
    [request] => SELECT SQL_CALC_FOUND_ROWS  wp_posts.ID
					 FROM wp_posts 
					 WHERE 1=1  AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
					 
					 ORDER BY RAND()
					 LIMIT 0, 3
    [posts] => Array
        (
            [0] => WP_Post Object
                (
                    [ID] => 4439
                    [post_author] => 3
                    [post_date] => 2024-07-30 15:29:07
                    [post_date_gmt] => 2024-07-30 19:29:07
                    [post_content] => 

CFB Client, IAMBIC has been awarded approximately $1M in grant funding from the National Science Foundation Small Business Innovation Research program. IAMBIC is an innovative shoe company disrupting the centuries-old footwear industry with their sizeless, precision-fit footwear driven by proprietary AI algorithms. This substantial funding from NSF enables IAMBIC to scale its cutting-edge precision-fit shoe design and manufacturing.

The Center for Biotechnology and its accelerator programs have been instrumental in assisting IAMBIC with their SBIR pursuits and commercialization development.

Read more about IAMBIC and their recent funding here.

[post_title] => IAMBIC Receives $1 Million NSF SBIR Phase II Grant [post_excerpt] => This substantial funding from NSF enables IAMBIC to scale its operations. [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => iambic-receives-1-million-nsf-sbir-phase-ii-grant [to_ping] => [pinged] => [post_modified] => 2024-08-09 15:38:43 [post_modified_gmt] => 2024-08-09 19:38:43 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4439 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [1] => WP_Post Object ( [ID] => 2913 [post_author] => 1 [post_date] => 2018-01-10 15:34:32 [post_date_gmt] => 2018-01-10 15:34:32 [post_content] => Celmatix, a next-generation women’s health company, has been awarded $4.5 million from Empire State Development’s New York City Regional Economic Development Council (REDC), to expand its headquarters in Manhattan. Piraye Yurttas Beim, PhD, Founder and CEO of Celmatix stated “New York State has been there for Celmatix every step of the way as we’ve transitioned from ambitious startup to innovative next generation women’s health company. From the training I received through New York State’s Center for Biotechnology program at Stony Brook University, to the support we received from the Empire State Development START-UP New York program when it was time to build our first lab, and now, with this award as we prepare to take the next step in the evolution of our company, we are honored to have continued support to grow and thrive in New York.” Additional Articles: pharmiweb [post_title] => Celmatix awarded $4.5M to expand in NYS [post_excerpt] => Celmatix receives $4.5 million to expand its headquarters in Manhattan. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => celmatix-awarded-4-5m-to-expand-in-nys [to_ping] => [pinged] => [post_modified] => 2018-02-02 19:23:34 [post_modified_gmt] => 2018-02-02 19:23:34 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/?p=2913 [menu_order] => 128 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [2] => WP_Post Object ( [ID] => 3660 [post_author] => 3 [post_date] => 2021-03-22 15:00:43 [post_date_gmt] => 2021-03-22 15:00:43 [post_content] =>

innovosource is partnering with Philips Image Guided Therapy Devices to identify partnership opportunities related to three specific technical challenges.

The goal is to connect motivated, industry partners with existing partnership nodes at research institutions to engage and initiate long-lasting relationships. Positive outcomes could result in company-funded POC projects, licensing, startup investment, and/or research partnerships.

This process is open and free to participate to all research institution partnership nodes (tech commercialization, gap funds/accelerators, corporate relations, research centers, faculty).

Learn more here: https://innovosource.lpages.co/bridge/

[post_title] => BRIDGE: University-Industry Proof of Concept Program [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => bridge-university-industry-proof-of-concept-program [to_ping] => [pinged] => [post_modified] => 2021-03-22 15:01:13 [post_modified_gmt] => 2021-03-22 15:01:13 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=3660 [menu_order] => 52 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [3] => WP_Post Object ( [ID] => 1568 [post_author] => 3 [post_date] => 2015-04-22 20:28:25 [post_date_gmt] => 2015-04-22 20:28:25 [post_content] => A new mathematical model that uses drug-target kinetics to predict how drugs work in vivo may provide a foundation to improve drug discovery, which is frequently hampered by the inability to predict effective doses of drugs. The discovery by Peter Tonge, a Professor of Chemistry and Radiology, and Director of Infectious Disease Research at the Institute for Chemical Biology and Drug Discovery (ICB & DD) at Stony Brook University, is co-authored by the Center for Biotechnology's Dr. Eleanor Allen, along with collaborators at Stony Brook University and AstraZeneca. Read the full study published advanced online in Nature Chemical Biology. Read more about the team from the Stony Brook Newsroom. [post_title] => New Mathematical Model May Improve Drug Discovery - Study Co-Authored by CFB's Dr. Eleanor Allen [post_excerpt] => A new mathematical model that uses drug-target kinetics to predict how drugs work in vivo may provide a foundation to improve drug discovery. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => new-mathematical-model-may-improve-drug-discovery-study-co-authored-by-cfbs-dr-eleanor-allen [to_ping] => [pinged] => [post_modified] => 2015-04-23 19:21:10 [post_modified_gmt] => 2015-04-23 19:21:10 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/new/?p=1568 [menu_order] => 204 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) ) [post_count] => 4 [current_post] => -1 [before_loop] => 1 [in_the_loop] => [post] => WP_Post Object ( [ID] => 4439 [post_author] => 3 [post_date] => 2024-07-30 15:29:07 [post_date_gmt] => 2024-07-30 19:29:07 [post_content] =>

CFB Client, IAMBIC has been awarded approximately $1M in grant funding from the National Science Foundation Small Business Innovation Research program. IAMBIC is an innovative shoe company disrupting the centuries-old footwear industry with their sizeless, precision-fit footwear driven by proprietary AI algorithms. This substantial funding from NSF enables IAMBIC to scale its cutting-edge precision-fit shoe design and manufacturing.

The Center for Biotechnology and its accelerator programs have been instrumental in assisting IAMBIC with their SBIR pursuits and commercialization development.

Read more about IAMBIC and their recent funding here.

[post_title] => IAMBIC Receives $1 Million NSF SBIR Phase II Grant [post_excerpt] => This substantial funding from NSF enables IAMBIC to scale its operations. [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => iambic-receives-1-million-nsf-sbir-phase-ii-grant [to_ping] => [pinged] => [post_modified] => 2024-08-09 15:38:43 [post_modified_gmt] => 2024-08-09 19:38:43 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4439 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [comment_count] => 0 [current_comment] => -1 [found_posts] => 260 [max_num_pages] => 87 [max_num_comment_pages] => 0 [is_single] => [is_preview] => [is_page] => [is_archive] => [is_date] => [is_year] => [is_month] => [is_day] => [is_time] => [is_author] => [is_category] => [is_tag] => [is_tax] => [is_search] => [is_feed] => [is_comment_feed] => [is_trackback] => [is_home] => 1 [is_privacy_policy] => [is_404] => [is_embed] => [is_paged] => [is_admin] => [is_attachment] => [is_singular] => [is_robots] => [is_favicon] => [is_posts_page] => [is_post_type_archive] => [query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0 [query_vars_changed:WP_Query:private] => [thumbnails_cached] => [allow_query_attachment_by_filename:protected] => [stopwords:WP_Query:private] => [compat_fields:WP_Query:private] => Array ( [0] => query_vars_hash [1] => query_vars_changed ) [compat_methods:WP_Query:private] => Array ( [0] => init_query_flags [1] => parse_tax_query ) )

IAMBIC Receives $1 Million NSF SBIR Phase II Grant

More Information

Celmatix awarded $4.5M to expand in NYS

More Information

BRIDGE: University-Industry Proof of Concept Program

More Information

New Mathematical Model May Improve Drug Discovery – Study Co-Authored by CFB’s Dr. Eleanor Allen

More Information